The Future of Prescient?

I have to admit that Prescient Therapeutics (ASX : PTX) hasn’t particularly¬†been on my radar, never really looked at it. With a market cap of $3m, I could probably be forgiven for this except for the fact that this forum is supposed to be about the Long Tail of the ASX, and PTX is pretty…

Invion, where is the data?

On August 17, Invion (ASX : IVX) provided an update on their INV103 program (recombinant Cpn10/Hsp10) in Systemic Lupus Erythematosus (SLE). Unfortunately, I got side-tracked by other things and haven’t had the bandwidth to comment on this announcement before now. I have previously provided detailed commentary on this company and will not be reviewing the technology in…

Clinical Trial Communication Matters

Over the past few months I have poked several companies in the eye for the appalling quality of their clinical communication. I have specifically paid attention to Novogen (ASX : NRT), Benitec (ASX : BLT), Regeneus (ASX : RGS) and a few others. It is my position is that there is a consistently low quality and sensationalist ethos…

Osprey Medical : Eagle or Turkey?

When I first started reading about Osprey Medical (ASX : OSP), I desperately wanted to find something good, to discover a small ASX-listed medtech company doing something great in the world. At a most basic level, there is a lot to like about OSP. It has some really good people. It seems to have¬†actually developed…

Neuren – A Can of Worms

Firstly, I would like to start this post by promoting another blog – specifically Trail to a Texas Trial. For anyone who is passionate about Rett Syndrome, it is powerful and emotional reading. I received a rather scathing retort from Melinda Lancaster, the owner of the site and the mother of a girl named Katelin who is…